)
Krishna Institute of Medical Sciences (KIMS) investor relations material
Krishna Institute of Medical Sciences Q3 25/26 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Achieved record Q3 FY26 revenue, surpassing INR 1,000 crore for the first time, with 29.2% year-over-year growth to ₹9,977 million and strong expansion in Maharashtra, Kerala, and Karnataka.
EBITDA remained stable at ₹2,041 million with a 20.4% margin, but PAT declined 43.9% year-over-year to ₹519 million due to higher finance costs and depreciation.
Bed capacity expanded to 6,464, with operational beds at 4,825 and occupancy at 49.0% in Q3 FY26.
Unaudited standalone and consolidated financial results for Q3 and nine months ended 31 December 2025 were approved, with unmodified review reports from auditors.
Board approved an increase in investment limit up to ₹100 crore for acquiring additional shares in Sarvejana Healthcare (Sunshine Hospital), a material subsidiary.
Financial highlights
Q3 FY26 total revenue: ₹10,029 million, up 29.2% year-over-year and 3.9% quarter-over-quarter.
EBITDA was INR 204 crore (₹2,041 million), down 0.4% year-over-year; EBITDA margin at 20.4% vs. 25.9% last year.
PAT at INR 52 crore (₹519 million), down from INR 93 crore (₹925 million) in Q3 FY25; EPS at INR 1.3, down 39.9% year-over-year.
Cash and equivalents stood at INR 206 crore as of December 31, 2025; net debt at INR 2,850 crore.
Standalone Q3 FY26 revenue: ₹4,419 million, up from ₹3,475 million in Q3 FY25; standalone net profit: ₹725 million.
Outlook and guidance
Focus on ramping up new hospitals and achieving break-even in recently launched units, with over 2,000 beds to be added through greenfield projects, acquisitions, and O&M opportunities.
Debt levels expected to moderate as major CapEx cycle concludes; future expansions may use alternative funding.
No material financial impact expected from new Indian labour codes effective November 2025; further evaluation will occur as rules are notified.
Double-digit growth in Telangana expected for the next 3-4 years due to new facilities; mature clusters may see slower growth thereafter.
Recent acquisitions expected to achieve break-even within 12 months, with ongoing operational improvements.
- Q1 FY25 delivered strong revenue, profit, and margin growth, with major expansion and acquisitions.KIMS
Q1 24/252 Feb 2026 - Strong revenue, margin, and profit growth, with major expansion and a 5-for-1 share split.KIMS
Q2 24/2515 Jan 2026 - Strong YoY revenue and EBITDA growth, ongoing expansion, and robust clinical milestones.KIMS
Q3 24/259 Jan 2026 - Strong FY25 growth with margin expansion, acquisitions, and new hospital launches.KIMS
Q4 24/257 Jan 2026 - Revenue up 26.8% YoY to INR 879 crore, but margins and PAT declined amid ongoing expansion.KIMS
Q1 25/266 Jan 2026 - Q2 FY26 revenue up 23.3% YoY, but EBITDA margin and PAT declined; expansion and mergers ongoing.KIMS
Q2 25/2618 Nov 2025
Next Krishna Institute of Medical Sciences earnings date
Next Krishna Institute of Medical Sciences earnings date
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
I can't remember the last time an app had such a positive impact on my investment process.
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
)
)
)
Frequently asked questions
Explore our global coverage